在基层医疗中支持2型糖尿病启动胰岛素治疗:Stepping Up实用性整群随机对照临床试验结果
该整群随机对照试验在澳大利亚维多利亚州74家基层医疗诊所比较Stepping Up照护模式与常规基层照护对2型糖尿病胰岛素启动正常化的效果,共纳入266例患者,随访12个月。结果显示干预组HbA1c改善更显著(组间平均差-0.6%,95%CI -0.9%至-0.3%),12个月时干预组105/151(70%)启动胰岛素,对照组25/115(22%)(OR 8.3,95%CI 4.5至15.4,P<0.001),且未出现严重低血糖事件。
要点
- 干预组12个月启动胰岛素比例70%(105/151),对照组22%(25/115),OR 8.3(95%CI 4.5至15.4,P<0.001)。
- HbA1c组间平均差-0.6%(95%CI -0.9%至-0.3%),支持干预组。
- 达到靶目标HbA1c(≤7%(53 mmol/mol))干预组36%(54例),对照组19%(22例),OR 2.2(95%CI 1.2至4.3,P=0.02)。
核心结论
- Stepping Up照护模式与基层医疗中胰岛素启动率增加及糖化血红蛋白改善相关,且未导致情绪健康状况恶化。
研究设计与样本
- 实用性整群随机对照临床试验,在澳大利亚维多利亚州纳入74家基层医疗诊所(平均每群4例患者,范围1-8例)和266例2型糖尿病患者,随访12个月。
- 纳入标准为诊所配有执业护士且至少有一名符合条件并知情同意的患者(HbA1c≥7.5%且已接受最大口服治疗)。
主要发现
- HbA1c两组均改善,组间平均差-0.6%(95%CI -0.9%至-0.3%),支持干预组。
- 12个月时干预组105/151(70%)启动胰岛素,对照组25/115(22%)(OR 8.3,95%CI 4.5至15.4,P<0.001)。
- 达到靶目标HbA1c(≤7%(53 mmol/mol))干预组54例(36%),对照组22例(19%)(OR 2.2,95%CI 1.2至4.3,P=0.02)。
- 12个月时抑郁症状未加重(PHQ-9:-1.1(3.5)vs -0.1(2.9),P=0.05)。
- 心理健康(AQoL心理成分总结:0.04(SD 0.16)vs -0.002(0.13),平均差0.04(95%CI 0.002至0.08),P=0.04)组间差异有统计学意义,支持干预组;身体健康(AQoL躯体成分总结:0.03(0.15)vs 0.02(0.13))及糖尿病特异性痛苦(5.6(15.5)vs -2.4(15.4))无显著差异。
关键数值与推荐
- 靶目标HbA1c定义为≤7%(53 mmol/mol)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To compare the effectiveness of a novel model of care ("Stepping Up") with usual primary care in normalising insulin initiation for type 2 diabetes, leading to improved glycated haemoglobin (HbA1c) levels.Design Cluster randomised controlled trial.Setting Primary care practices in Victoria, Australia, with a practice nurse and at least one consenting eligible patient (HbA1c ≥7.5% with maximal oral treatment).Participants 266 patients with type 2 diabetes and 74 practices (mean cluster size 4 (range 1-8) patients), followed up for 12 months.Intervention The Stepping Up model of care intervention involved theory based change in practice systems and reorientation of the roles of health professionals in the primary care diabetes team. The core components were an enhanced role for the practice nurse in leading insulin initiation and mentoring by a registered nurse with diabetes educator credentials.Main outcome measures The primary endpoint was change in HbA1c. Secondary endpoints included the proportion of participants who transitioned to insulin, proportion who achieved target HbA1c, and a change in depressive symptoms (patient health questionnaire, PHQ-9), diabetes specific distress (problem areas in diabetes scale, PAID), and generic health status (assessment of quality of life instrument, AQoL-8D).Results HbA1c improved in both arms, with a clinically significant between arm difference (mean difference -0.6%, 95% confidence interval -0.9% to -0.3%), favouring the intervention. At 12 months, in intervention practices, 105/151 (70%) of participants had started insulin, compared with 25/115 (22%) in control practices (odds ratio 8.3, 95% confidence interval 4.5 to 15.4, P<0.001). Target HbA1c (≤7% (53 mmol/mol)) was achieved by 54 (36%) intervention participants and 22 (19%) control participants (odds ratio 2.2, 1.2 to 4.3, P=0.02). Depressive symptoms did not worsen at 12 months (PHQ-9: -1.1 (3.5) v -0.1 (2.9), P=0.05). A statistically significant difference was found between arms in the mean change in mental health (AQoL mental component summary: 0.04 (SD 0.16) v -0.002 (0.13), mean difference 0.04 (95% confidence interval 0.002 to 0.08), P=0.04), favouring the intervention, but no significant difference in physical health (AQoL physical component summary: 0.03 (0.15) v 0.02 (0.13)) nor diabetes specific distress (5.6 (15.5) v -2.4 (15.4)). No severe hypoglycaemia events were reported.Conclusions The Stepping Up model of care was associated with increased insulin initiation rates in primary care, and improvements in glycated haemoglobin without worsening emotional wellbeing.Trial registration Australian and New Zealand Clinical Trials Registry ACTRN12612001028897.
引用
- Furler J, O'Neal D, Speight J, et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ. 2017. PMID: 28274941. doi:10.1136/bmj.j783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。